This case report compares outcomes of gastric manec and conventional adenocarcinoma, indicating worse survival rates.
Gastric MANEC (gMANEC) is a rare tumor composed of at least 30% each adenocarcinoma and neuroendocrine carcinoma (NEC) components. A 52‐year‐old male underwent total D2 gastrectomy for gastric cancer. Final pathology revealed MANEC. We compare outcomes and mortality rates between gastric MANEC and conventional adenocarcinoma. MANEC has poorer disease‐free survival (DFS) and post‐recurrence survival (PRS), and higher risk of distant recurrence, compared with clear adenocarcinoma. Rigorous follow‐up and adjuvant therapy tailored to the more aggressive component are advised.
No takes yet. Share an insight, caveat, or question.
Aikaterini et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: